Andrew D. Schiermeier

2018

In 2018, Andrew D. Schiermeier earned a total compensation of $2.9M as Executive Vice President, Development and Corporate Strategy at Intellia Therapeutics.

Compensation breakdown

Bonus$182,600
Option Awards$2,028,554
Salary$408,934
Stock Awards$295,550
Other$9,668
Total$2,925,306

Schiermeier received $2M in option awards, accounting for 69% of the total pay in 2018.

Schiermeier also received $182.6K in bonus, $408.9K in salary, $295.6K in stock awards and $9.7K in other compensation.

Rankings

In 2018, Andrew D. Schiermeier's compensation ranked 3,971st out of 14,244 executives tracked by ExecPay. In other words, Schiermeier earned more than 72.1% of executives.

ClassificationRankingPercentile
All
3,971
out of 14,244
72nd
Division
Manufacturing
1,461
out of 5,759
75th
Major group
Chemicals And Allied Products
519
out of 2,122
76th
Industry group
Drugs
436
out of 1,811
76th
Industry
In Vitro and In Vivo Diagnostic Substances
6
out of 72
92nd
Source: SEC filing on April 16, 2019.

Schiermeier's colleagues

We found four more compensation records of executives who worked with Andrew D. Schiermeier at Intellia Therapeutics in 2018.

2018

John Leonard

Intellia Therapeutics

Chief Executive Officer

2018

José Rivera

Intellia Therapeutics

General Counsel

2018

Glenn Goddard

Intellia Therapeutics

Chief Financial Officer

2018

Graeme Bell

Intellia Therapeutics

Chief Financial Officer

News

In-depth

You may also like